A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) (NCT07499544)
A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)
🩺 Plain-English Summary (8th-Grade Level)
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Who can join: Review the eligibility criteria below.
Location: Site 201 — Garden Grove, California
Age range: 12 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Site 201 — Garden Grove, California
- Site 101 — Changchun, Jilin
- Site 104 — Kashgar, Xinjiang Uygur Autonomous Region
- Site 103 — Ürümqi, Xinjiang Uygur Autonomous Region
- Site 303 — Rawalpindi, Punjab Province
- Site 301 — Karachi, Sindh
- Site 302 — Karachi, Sindh
📞 Contact the Study Coordinator
Phone: +86 13552466248
Email: wenjiaying@hhhbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Hepatitis D Infection
Explore by condition: All Chronic Hepatitis D Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.